• 09 AUG 2021

    PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Company’s common stock is expected to begin trading on The Nasdaq Capital Market on August 10, 2021, under the symbol

    Read more →
    • 02 AUG 2021

    PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCBD) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that The Nasdaq Stock Market LLC (Nasdaq) has approved the listing of the Company’s common stock on Nasdaq. The Company’s common stock

    Read more →
    • 22 JUL 2021

    PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment

    LAGUNA HILLS, CA, July 22, 2021 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCBD), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that three independent industry publications mention PharmaCyte and/or its past clinical trials and their contributions to prior and future work

    Read more →
    • 14 JUL 2021

    PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCBD), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the production and shipping of test materials and study plan designs for the biocompatibility studies requested by the U.S. Food and Drug Administration (FDA)

    Read more →
    • 12 JUL 2021

    PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank

    LAGUNA HILLS, CA, July 12, 2021—(BUSINESS WIRE)—PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that after 3 years of storage in a vapor phase of liquid nitrogen, the original cytochrome P450 expressing cells from PharmaCyte’s Master Cell

    Read more →
    • 09 JUL 2021

    PharmaCyte Biotech Announces Reverse Stock Split

    LAGUNA HILLS, CA, July 9, 2021—(BUSINESS WIRE)—PharmaCyte Biotech, Inc. (OTCQB: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will effect a 1-for-1,500 reverse stock split of its shares of common stock, leaving the Company with only

    Read more →
    • 08 JUL 2021

    PharmaCyte Biotech Announces Results of Vote at Annual Meeting of Stockholders

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that all 4 proposals presented to the Company’s stockholders for a vote at the 2021 Annual Meeting of Stockholders have passed. PharmaCyte’s 2021 Annual Meeting

    Read more →
    • 24 JUN 2021

    PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold

    LAGUNA HILLS, CA, June 24, 2021–(BUSINESS WIRE)—PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box® , today an-nounced the efforts being undertaken by the Company to have the U.S. Food and Drug Admin-istration (FDA) clinical hold lifted. These efforts are

    Read more →
    • 22 JUN 2021

    PharmaCyte Biotech Announces Shareholders Vote to Increase the Authorized Capital

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box® , announced today that, unofficially, a majority of PharmaCyte’s shareholders have voted in favor of Proposal No. 2, the proposal to increase the authorized number of shares of

    Read more →
    • 18 JUN 2021

    PharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available

    LAGUNA HILLS, CA, June 18, 2021–(BUSINESS WIRE)—PharmaCyte Biotech, Inc. (“Company”) (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box® , announced today that its 2021 Annual Meeting of Stockholders, held on June 16, 2021, has been adjourned until June 30, 2021, at 11:00

    Read more →